Global market valuation was derived through revenue mapping and patient volume analysis. The methodology included:
Identification of 25+ key pharmaceutical and biotechnology companies across North America, Europe, Asia-Pacific, and Latin America
Product mapping across corticosteroids, monoclonal antibodies (rituximab, sutimlimab), immunosuppressants (azathioprine, cyclosporine, mycophenolate), complement inhibitors, and splenectomy-related interventions
Analysis of reported and modeled annual revenues specific to autoimmune hemolytic anemia and related rare disease portfolios
Coverage of manufacturers representing 75-80% of global market share in 2024
Extrapolation using bottom-up (patient volume × treatment cost by country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations, incorporating epidemiology data, treatment rates, and therapy duration assumptions